Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 121 to 124 of 124 entries
Sorted by: Best Match Show Resources per page
Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model.

Antiviral research

Cochin M, Touret F, Driouich JS, Moureau G, Petit PR, Laprie C, Solas C, de Lamballerie X, Nougairède A.
PMID: 34838583
Antiviral Res. 2021 Nov 24;197:105212. doi: 10.1016/j.antiviral.2021.105212. Epub 2021 Nov 24.

Drug repositioning has been used extensively since the beginning of the COVID-19 pandemic in an attempt to identify antiviral molecules for use in human therapeutics. Hydroxychloroquine and azithromycin have shown inhibitory activity against SARS-CoV-2 replication in different cell lines....

Cite
Cochin M, Touret F, Driouich JS, et al. Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model. Antiviral Res. 2021;197:105212doi: 10.1016/j.antiviral.2021.105212.
Cochin, M., Touret, F., Driouich, J. S., Moureau, G., Petit, P. R., Laprie, C., Solas, C., de Lamballerie, X., & Nougairède, A. (2021). Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model. Antiviral research, 197105212. https://doi.org/10.1016/j.antiviral.2021.105212
Cochin, Maxime, et al. "Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model." Antiviral research vol. 197 (2021): 105212. doi: https://doi.org/10.1016/j.antiviral.2021.105212
Cochin M, Touret F, Driouich JS, Moureau G, Petit PR, Laprie C, Solas C, de Lamballerie X, Nougairède A. Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model. Antiviral Res. 2021 Nov 24;197:105212. doi: 10.1016/j.antiviral.2021.105212. Epub 2021 Nov 24. PMID: 34838583; PMCID: PMC8611861.
Copy Download .nbib Format: NLM
Early Trajectory of Estimated Glomerular Filtration Rate and Long-term Advanced Kidney and Cardiovascular Complications in Type 1 Diabetes.

Diabetes care

Perkins BA, Bebu I, Gao X, Karger AB, Hirsch IB, Karanchi H, Molitch ME, Zinman B, Lachin JM, de Boer IH.
PMID: 35015817
Diabetes Care. 2022 Jan 06; doi: 10.2337/dc21-1883. Epub 2022 Jan 06.

OBJECTIVE: Rapid loss of estimated glomerular filtration rate (eGFR) within its normal range has been proposed as a strong predictor of future kidney disease. We investigated this association of eGFR slope early in the course of type 1 diabetes...

Cite
Perkins BA, Bebu I, Gao X, et al. Early Trajectory of Estimated Glomerular Filtration Rate and Long-term Advanced Kidney and Cardiovascular Complications in Type 1 Diabetes. Diabetes Care. 2022;doi: 10.2337/dc21-1883.
Perkins, B. A., Bebu, I., Gao, X., Karger, A. B., Hirsch, I. B., Karanchi, H., Molitch, M. E., Zinman, B., Lachin, J. M., & de Boer, I. H. (2022). Early Trajectory of Estimated Glomerular Filtration Rate and Long-term Advanced Kidney and Cardiovascular Complications in Type 1 Diabetes. Diabetes care, . https://doi.org/10.2337/dc21-1883
Perkins, Bruce A, et al. "Early Trajectory of Estimated Glomerular Filtration Rate and Long-term Advanced Kidney and Cardiovascular Complications in Type 1 Diabetes." Diabetes care vol. (2022). doi: https://doi.org/10.2337/dc21-1883
Perkins BA, Bebu I, Gao X, Karger AB, Hirsch IB, Karanchi H, Molitch ME, Zinman B, Lachin JM, de Boer IH. Early Trajectory of Estimated Glomerular Filtration Rate and Long-term Advanced Kidney and Cardiovascular Complications in Type 1 Diabetes. Diabetes Care. 2022 Jan 06; doi: 10.2337/dc21-1883. Epub 2022 Jan 06. PMID: 35015817.
Copy Download .nbib Format: NLM
Comparison of central laboratory HbA1c measurements obtained from a capillary collection versus a standard venous whole blood collection in the GRADE and EDIC studies.

PloS one

Nathan DM, Krause-Steinrauf H, Braffett BH, Arends VL, Younes N, McGee P, Lund C, Johnson M, Lorenzi G, Gao X, Steffes MW, Lachin JM.
PMID: 34780485
PLoS One. 2021 Nov 15;16(11):e0257154. doi: 10.1371/journal.pone.0257154. eCollection 2021.

BACKGROUND: We compared HbA1c values obtained from capillary blood collection kits versus venous whole blood collections in study participants with type 1 or type 2 diabetes.METHODS: A total of 122 subjects, 64 with type 2 diabetes participating in the...

Cite
Nathan DM, Krause-Steinrauf H, Braffett BH, et al. Comparison of central laboratory HbA1c measurements obtained from a capillary collection versus a standard venous whole blood collection in the GRADE and EDIC studies. PLoS One. 2021;16(11):e0257154doi: 10.1371/journal.pone.0257154.
Nathan, D. M., Krause-Steinrauf, H., Braffett, B. H., Arends, V. L., Younes, N., McGee, P., Lund, C., Johnson, M., Lorenzi, G., Gao, X., Steffes, M. W., Lachin, J. M. (2021). Comparison of central laboratory HbA1c measurements obtained from a capillary collection versus a standard venous whole blood collection in the GRADE and EDIC studies. PloS one, 16(11), e0257154. https://doi.org/10.1371/journal.pone.0257154
Nathan, David M, et al. "Comparison of central laboratory HbA1c measurements obtained from a capillary collection versus a standard venous whole blood collection in the GRADE and EDIC studies." PloS one vol. 16,11 (2021): e0257154. doi: https://doi.org/10.1371/journal.pone.0257154
Nathan DM, Krause-Steinrauf H, Braffett BH, Arends VL, Younes N, McGee P, Lund C, Johnson M, Lorenzi G, Gao X, Steffes MW, Lachin JM. Comparison of central laboratory HbA1c measurements obtained from a capillary collection versus a standard venous whole blood collection in the GRADE and EDIC studies. PLoS One. 2021 Nov 15;16(11):e0257154. doi: 10.1371/journal.pone.0257154. eCollection 2021. PMID: 34780485; PMCID: PMC8592405.
Copy Download .nbib Format: NLM
Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model.

Antiviral research

Cochin M, Touret F, Driouich JS, Moureau G, Petit PR, Laprie C, Solas C, de Lamballerie X, Nougairède A.
PMID: 34838583
Antiviral Res. 2022 Jan;197:105212. doi: 10.1016/j.antiviral.2021.105212. Epub 2021 Nov 24.

Drug repositioning has been used extensively since the beginning of the COVID-19 pandemic in an attempt to identify antiviral molecules for use in human therapeutics. Hydroxychloroquine and azithromycin have shown inhibitory activity against SARS-CoV-2 replication in different cell lines....

Cite
Cochin M, Touret F, Driouich JS, et al. Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model. Antiviral Res. 2021;197:105212doi: 10.1016/j.antiviral.2021.105212.
Cochin, M., Touret, F., Driouich, J. S., Moureau, G., Petit, P. R., Laprie, C., Solas, C., de Lamballerie, X., & Nougairède, A. (2022). Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model. Antiviral research, 197105212. https://doi.org/10.1016/j.antiviral.2021.105212
Cochin, Maxime, et al. "Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model." Antiviral research vol. 197 (2022): 105212. doi: https://doi.org/10.1016/j.antiviral.2021.105212
Cochin M, Touret F, Driouich JS, Moureau G, Petit PR, Laprie C, Solas C, de Lamballerie X, Nougairède A. Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model. Antiviral Res. 2022 Jan;197:105212. doi: 10.1016/j.antiviral.2021.105212. Epub 2021 Nov 24. PMID: 34838583; PMCID: PMC8611861.
Copy Download .nbib Format: NLM
Showing 121 to 124 of 124 entries